OneSkin is a skin longevity company founded by a team of female PhD scientists that applies longevity science to extend "skinspan" by targeting underlying mechanisms of aging. Its core technology centers on a proprietary peptide, OS-01, designed to reduce the burden of senescent cells that drive inflammation, collagen breakdown and visible signs of aging. Product offerings include topical and supplement SKUs such as OS-01 FACE, BODY, EYE and the recently launched OS-01 LIP and HAIR. The brand has built a passionate consumer community and counts celebrities such as Jennifer Aniston, Camila Alves McConaughey and Katy Perry among its fans. OneSkin sells its products direct-to-consumer at oneskin.co and emphasizes rigorous scientific research and bioinformatics in product development. The company announced the Series A from San Francisco, signaling a step toward scaling the brand and its science-driven product pipeline. OneSkin develops science‑led topical skin longevity treatments built around its proprietary peptide OS‑01, which the company says is patented and published in peer‑reviewed journals. The brand formulates OS‑01 into topical supplements designed to modulate cellular aging and prevent accumulation of senescent cells. OneSkin reports clinical testing and lab replication of skin biological age reversal and has collected thousands of customer testimonials since launching its product line in 2021. Founded in 2016 by four Brazilian PhD scientists, the company positions itself at the intersection of beauty and wellness with a research‑first approach. OneSkin will use new funding to accelerate research, develop novel formulas, expand longevity solutions, and scale go‑to‑market capacity through increased human capital and new sales channels. The company is headquartered in San Francisco and has raised a total of $20M to date.

Total raised

$20M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2025